San Antonio BC 2005

Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

Dennis Slamon, UCLA School of Medicine, Los Angeles
It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast cancer - provided agents such as docetaxel and trastuzumab are also included, according to the findings of the BCIRG 006 trial reported at the San Antonio Breast Cancer Symposium.
COMMENT: Norman Wolmark, NSABP foundation, Pittsburg


Click here for all the interviews from San Antonio Breast Cancer Symposium 2005

Similar Interviews

  • Audio Journal of Oncology in Advance - January 15th, 2007 - HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer
  • IAN SMITH, Royal Marsden Hospital, London REFERENCE: Lancet 369:29 Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast

  • Audio Journal of Oncology 14.1, February 2006
  • Reporting from: San Antonio Breast Cancer Symposium 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price,

  • Breast Cancer: Further Support for Trastuzumab from Combined Analysis
  • Edward Romond Edward Romond, University of Kentucky, Lexington More data for trastuzumab comes from a combined analysis of two large, parallel trials:

    Post a comment

    Subscribe to Audio Medica Podcast